Challenges and benefits in harnessing platform processes for viral vector manufacture

As the demand for AAV and lentiviral vector-driven gene therapies continues to grow, the manufacturing space must overcome manufacturing challenges including issues of cost, scalability, and consistency. David McCall, Senior Editor, BioInsights, spoke with Dark Horse Consulting Group’s Scott Cross, Christina Fuentes, and Jacob Staudhammer (pictured left to right) about the current utility and future potential of platform technologies and processes for viral vector manufacturing.

Please enter your email to access content Read now